HC Wainwright Has Negative Forecast for Alector Q3 Earnings

Alector, Inc. (NASDAQ:ALEC) – Investment analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Alector in a note issued to investors on Friday, August 7th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.23) for the quarter, down from their previous estimate of ($0.22). The consensus estimate for Alector’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Alector’s Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($1.00) EPS, FY2029 earnings at ($1.00) EPS and FY2030 earnings at ($0.94) EPS.

Alector (NASDAQ:ALEC) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The business had revenue of $3.32 million for the quarter, compared to analyst estimates of $1.71 million. Alector had a negative net margin of 850.13% and a negative return on equity of 531.03%.

A number of other brokerages also recently issued reports on ALEC. Wall Street Zen raised Alector from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Morgan Stanley reaffirmed an “underweight” rating and set a $2.00 price objective on shares of Alector in a report on Monday, May 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alector in a research report on Friday, July 31st. Finally, Cantor Fitzgerald upgraded Alector from a “neutral” rating to an “overweight” rating in a research report on Wednesday, April 15th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.62.

Alector Price Performance

Shares of ALEC opened at $1.69 on Tuesday. The company has a current ratio of 5.26, a quick ratio of 5.26 and a debt-to-equity ratio of 0.80. The stock’s 50 day moving average is $1.68 and its two-hundred day moving average is $2.01. Alector has a twelve month low of $1.09 and a twelve month high of $3.40. The firm has a market capitalization of $188.71 million, a PE ratio of -1.54 and a beta of 0.60.

Insider Activity

In related news, CEO Arnon Rosenthal sold 87,216 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $1.97, for a total value of $171,815.52. Following the sale, the chief executive officer directly owned 2,367,206 shares of the company’s stock, valued at approximately $4,663,395.82. This trade represents a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Neil Lindsay Berkley sold 19,360 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $1.97, for a total transaction of $38,139.20. Following the transaction, the chief financial officer directly owned 379,900 shares of the company’s stock, valued at $748,403. This trade represents a 4.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 115,760 shares of company stock worth $227,734. Insiders own 8.30% of the company’s stock.

Hedge Funds Weigh In On Alector

Large investors have recently modified their holdings of the company. Jane Street Group LLC lifted its stake in shares of Alector by 4.7% in the 1st quarter. Jane Street Group LLC now owns 256,551 shares of the company’s stock valued at $316,000 after purchasing an additional 11,618 shares in the last quarter. Strs Ohio acquired a new position in Alector during the first quarter valued at approximately $126,000. Geode Capital Management LLC lifted its position in Alector by 1.0% during the second quarter. Geode Capital Management LLC now owns 1,982,068 shares of the company’s stock valued at $2,775,000 after buying an additional 19,970 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of Alector in the second quarter worth $30,000. Finally, XTX Topco Ltd raised its stake in shares of Alector by 125.2% in the 2nd quarter. XTX Topco Ltd now owns 73,338 shares of the company’s stock valued at $103,000 after acquiring an additional 40,767 shares during the period. 85.83% of the stock is currently owned by hedge funds and other institutional investors.

About Alector

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.